H.C. Wainwright lowered the firm’s price target on 89bio to $29 from $31 and keeps a Buy rating on the shares post the Q1 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB:
- ‘Jump on the Bandwagon,’ Says Bank of America About These 2 Stock Picks
- 89bio assumed with a Buy at BofA
- 89bio Enhances Board with Biopharma Veteran Martin Babler
- 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Questions or Comments about the article? Write to editor@tipranks.com